CMS May Decide to Permit Labs to Bill for Certain Tests Provided to Outpatients

by Mintz Levin - Health Law & Policy Matters
Contact

In the recently published proposed rule related to the CY 2018 Hospital Outpatient Prospective Payment System (OPPS), the Centers for Medicare & Medicaid Services (CMS) announced that it is considering changes to the regulation governing the date of service (DOS) for clinical laboratory and pathology specimens.  The DOS rules are important to laboratories and hospitals because they dictate which party must bill Medicare for certain laboratory testing performed on stored specimens collected during a hospital procedure but ordered after the patient has left the hospital.  If revisions are ultimately finalized, the proposal could have significant business implications for independent laboratories and hospitals.

With few exceptions, the Medicare payment amount associated with an outpatient encounter covers all services provided during the outpatient stay, including any clinical laboratory diagnostic test (CDLT) as well as the technical component (TC) of anatomic pathology (AP) services (the professional component is one of the aforementioned exemptions).   Prior to CY 2014, a hospital could bill Medicare for CDLTs ordered during an outpatient stay if the corresponding CPT codes appeared on the Medicare Clinical Laboratory Fee Schedule (CLFS).  As explained in a previous post, this policy changed in CY 2014 when CMS decided to package certain CDLTs under OPPS.  Under this policy, a hospital can receive separate reimbursement for CDLTs associated with an outpatient stay only if the CDLT at issue is:

  • the only service provided to a beneficiary on a claim;
  • a preventive service;
  • a molecular pathology test; or
  • an advanced diagnostic laboratory test (ADLT), as defined under the Protecting Access to Medicare Act of 2014.

The packaging policy does not, however, cover the TC of AP services provided to a hospital outpatient.  In most circumstances, Medicare has required a laboratory to bill the TC back to the hospital, but the hospital can bill Medicare for the TC under OPPs.  In a previous post, we discussed a legislative exception to this rule that Congress declined to extend back in June 2012.

Depending on the DOS, CDLTs and the TC of AP services may be subject to the packaging policy even if ordered after the patient has left the hospital.   Generally speaking, the DOS for a CDLT and the TC of AP services is the date of collection, but a different set of rules apply to stored specimens (e.g., tissue collected during biopsy procedures occurring in the hospital).   For a test performed on a specimen that has been stored for 30 calendar days or less, the DOS is the date the test was performed only if:

  • the test was ordered by the patient’s physician at least 14 days after discharge;
  • the specimen was collected during a hospital surgical procedure;
  • collection of the specimen at any other time would have been medically inappropriate;
  • the results of the test were not used to guide treatment provided during the hospital stay; and
  • the test was reasonable and medically necessary for the treatment of an illness.

This regulatory provision, implemented in CY 2007, is known in the lab industry as the “14-Day Rule.” All other testing associated with specimens stored for less than 30 calendar days is subject to the packaging policy, which means that the laboratory must bill the hospital rather than Medicare for those services.

The proliferation of molecular pathology testing technology, coupled with the implementation of the packaging policy a few years ago, has strained relationships between many hospitals and laboratories.  What often happens is that an oncologist or other physician sees a patient following a biopsy procedure conducted during an outpatient stay, and that physician orders molecular pathology testing in an effort to determine the patient’s course of cancer treatment based on his or her genetic markers.  Upon receipt of the test order, the laboratory obtains the stored specimen from the hospital.  In some cases, the test order meets the requirements of the 14-Day Rule, and the laboratory can bill Medicare directly for the testing.  But for various reasons that is not always the case, and the laboratory has no choice but to bill the hospital for the services. The hospital is then unhappy about bearing the expense of testing that is ordered after, and is unrelated to, the outpatient stay.

With this backdrop in mind, laboratory stakeholders have provided feedback to CMS regarding the “operational issues the current laboratory DOS policy creates for hospitals and laboratories with regard to molecular pathology tests and laboratory tests they expect will be designated by CMS as ADLTs.”  While these particular tests are not subject to the packaging policy (and thus hospitals can bill and receive payment at CLFS rates), laboratories still cannot seek payment from Medicare directly for any testing ordered within 14 days of discharge, and many hospitals are resistant to billing Medicare for testing performed by an unaffiliated laboratory.  The proposed rule details a number of additional concerns with the current DOS policy, including decreased beneficiary access to necessary laboratory tests and therapies that could result from a hospital delaying the submission of test orders to avoid application of the 14-Day Rule.

In recognition of the issues raised by stakeholders, CMS is considering potential modifications to the DOS policy that would allow laboratories to bill Medicare directly for certain laboratory tests excluded from the packaging policy.  CMS proposed three potential approaches:

  • creating an exception to the DOS rules that would allow laboratories to bill separately for molecular pathology tests and ADLTs, even if ordered within 14 days of the patient’s discharge, as long as certain other conditions are met;
  • applying the above exception ONLY to ADLTs because the same “access to care” concerns may not exist for molecular pathology tests (which, according to CMS, hospitals may perform); and
  • adding an exception to the “under arrangements” rules for molecular pathology tests and ADLTs excluded from the OPPS packaging policy.

Comments on the proposed rule are due by September 11, 2017.  CMS will issue the final OPPS rule for CY 2018 before the end of CY 2017, but it is unclear whether it will include final changes to the DOS policy.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin - Health Law & Policy Matters | Attorney Advertising

Written by:

Mintz Levin - Health Law & Policy Matters
Contact
more
less

Mintz Levin - Health Law & Policy Matters on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.